|
PIN4 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 4 |
|
|
|
|
PITPNA |
phosphatidylinositol transfer protein alpha |
- Role of second messengers in netrin-1 signaling
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
- 1,2-diacyl-sn-glycero-3-phosphoinositol
- (Z,Z)-4-Hydroxy-N,N,N-Trimethyl-10-Oxo-7-[(1-Oxo-9-Octadecenyl)Oxy]-3,5,9-Trioxa-4-Phosphaheptacos-18-En-1-Aminium-4-Oxide
|
|
|
PKIA |
cAMP-dependent protein kinase inhibitor alpha |
|
- 3,5-Diiodotyrosine
- Hydroxyfasudil
- (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
- (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE
- (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
- (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE
- N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE
- (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
- (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- H-89
- 5-(2-methylpiperazine-1-sulfonyl)isoquinoline
- N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE
- 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
- 3-pyridin-4-yl-1H-indazole
- 5-benzyl-1,3-thiazol-2-amine
- 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium
- Fasudil
- Myristic acid
- A-674563
- 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE
- Y-27632
|
|
|
PLCG1 |
phospholipase C gamma 1 |
- ISG15 antiviral mechanism
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PLCG1 events in ERBB2 signaling
- DAG and IP3 signaling
- PLC-gamma1 signalling
- Synthesis of IP3 and IP4 in the cytosol
- Downstream signal transduction
- Generation of second messenger molecules
- Role of phospholipids in phagocytosis
- Role of phospholipids in phagocytosis
- PECAM1 interactions
- EGFR interacts with phospholipase C-gamma
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Role of second messengers in netrin-1 signaling
- VEGFR2 mediated cell proliferation
- VEGFR2 mediated cell proliferation
- Constitutive Signaling by EGFRvIII
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 point mutants in cancer
- RET signaling
- Activated NTRK2 signals through PLCG1
- Activated NTRK2 signals through PLCG1
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Activated NTRK3 signals through PLCG1
- Activated NTRK3 signals through PLCG1
- FCGR3A-mediated IL10 synthesis
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
|
|
|
PLCG2 |
phospholipase C gamma 2 |
- GPVI-mediated activation cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Synthesis of IP3 and IP4 in the cytosol
- Generation of second messenger molecules
- Role of phospholipids in phagocytosis
- DAP12 signaling
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- CLEC7A (Dectin-1) signaling
- CLEC7A (Dectin-1) signaling
- Dectin-2 family
- Dectin-2 family
- Erythropoietin activates Phospholipase C gamma (PLCG)
- FCGR3A-mediated IL10 synthesis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
|
|
PLD1 |
phospholipase D1 |
- Synthesis of PG
- Synthesis of PA
- Role of phospholipids in phagocytosis
- Neutrophil degranulation
|
- Choline
- LAX-101
- Choline salicylate
|
|
|
PLD2 |
phospholipase D2 |
- Synthesis of PG
- Synthesis of PA
- Role of phospholipids in phagocytosis
|
- Choline
- Choline salicylate
|
|
|
PLEC |
plectin |
- Assembly of collagen fibrils and other multimeric structures
- Caspase-mediated cleavage of cytoskeletal proteins
- Type I hemidesmosome assembly
|
|
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Epidermolysis bullosa, hemidesmosomal, including: Epidermolysis bullosa, generalized atrophic benign (GABEB); Epidermolysis bullosa simplex with pyloric atresia (EBS-PA); Epidermolysis bullosa simplex with muscular dystrophy (EBS-MD); Epidermolysis bullosa simplex, Ogna type (EBS-Ogna)
|
|
PLSCR1 |
phospholipid scramblase 1 |
|
|
|
|
PML |
PML nuclear body scaffold |
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of ubiquitinylation proteins
- Regulation of TP53 Activity through Acetylation
- Interferon gamma signaling
- Regulation of RUNX1 Expression and Activity
- Regulation of PTEN localization
- HCMV Early Events
|
|
- Acute myeloid leukemia (AML)
|
|
PPARG |
peroxisome proliferator activated receptor gamma |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- MECP2 regulates transcription factors
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Mesalazine
- Valproic acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Nateglinide
- Sulfasalazine
- Clofazimine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Amiodarone
- Pioglitazone
- Mitiglinide
- Bezafibrate
- Flufenamic acid
- Resveratrol
- Phthalic Acid
- Capric acid
- Doconexent
- Oleic Acid
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- Reglitazar
- Elafibranor
- AMG-131
- CLX-0921
- Muraglitazar
- Ertiprotafib
- Ragaglitazar
- Tesaglitazar
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- 9(S)-HODE
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- Indeglitazar
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- Triclosan
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- Aleglitazar
- Clinofibrate
- Cannabidiol
- Lobeglitazone
- Ciglitazone
- Dexibuprofen
- Omega-3 fatty acids
- Curcumin
- Arhalofenate
- Isoflavone
- Naveglitazar
- Fenofibric acid
- Fish oil
- Medical Cannabis
- Nabiximols
- Darglitazone
- Curcumin sulfate
|
- Type II diabetes mellitus
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Thyroid cancer
|
|
PPM1A |
protein phosphatase, Mg2+/Mn2+ dependent 1A |
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Energy dependent regulation of mTOR by LKB1-AMPK
|
|
|
|
PPM1B |
protein phosphatase, Mg2+/Mn2+ dependent 1B |
- ISG15 antiviral mechanism
|
|
|
|
PPP2CB |
protein phosphatase 2 catalytic subunit beta |
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Spry regulation of FGF signaling
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Integration of energy metabolism
- PP2A-mediated dephosphorylation of key metabolic factors
- DARPP-32 events
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- ERK/MAPK targets
- ERKs are inactivated
- MASTL Facilitates Mitotic Progression
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- CTLA4 inhibitory signaling
- Platelet sensitization by LDL
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Signaling by GSK3beta mutants
- S33 mutants of beta-catenin aren't phosphorylated
- S37 mutants of beta-catenin aren't phosphorylated
- S45 mutants of beta-catenin aren't phosphorylated
- T41 mutants of beta-catenin aren't phosphorylated
- APC truncation mutants have impaired AXIN binding
- AXIN missense mutants destabilize the destruction complex
- Truncations of AMER1 destabilize the destruction complex
- RHO GTPases Activate Formins
- RAF activation
- Negative regulation of MAPK pathway
- Regulation of TP53 Degradation
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Mitotic Prometaphase
- Cyclin D associated events in G1
- Cyclin A/B1/B2 associated events during G2/M transition
- Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
- EML4 and NUDC in mitotic spindle formation
|
|
|
|
PPP3CB |
protein phosphatase 3 catalytic subunit beta |
- DARPP-32 events
- Calcineurin activates NFAT
- Calcineurin activates NFAT
- FCERI mediated Ca+2 mobilization
- Ca2+ pathway
- CLEC7A (Dectin-1) induces NFAT activation
- ROBO receptors bind AKAP5
|
|
|
|
PPP5C |
protein phosphatase 5 catalytic subunit |
- Negative regulation of MAPK pathway
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- ESR-mediated signaling
|
|
|
|
PRCC |
proline rich mitotic checkpoint control factor |
- mRNA Splicing - Major Pathway
|
|
|
|
PRDX1 |
peroxiredoxin 1 |
- Detoxification of Reactive Oxygen Species
- TP53 Regulates Metabolic Genes
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
- Zinc
- Copper
- Artenimol
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
PRKACA |
protein kinase cAMP-activated catalytic subunit alpha |
- PKA-mediated phosphorylation of CREB
- PKA-mediated phosphorylation of key metabolic factors
- Triglyceride catabolism
- PKA activation
- PKA activation in glucagon signalling
- DARPP-32 events
- Regulation of PLK1 Activity at G2/M Transition
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Rap1 signalling
- Regulation of insulin secretion
- Vasopressin regulates renal water homeostasis via Aquaporins
- VEGFA-VEGFR2 Pathway
- CREB1 phosphorylation through the activation of Adenylate Cyclase
- CREB1 phosphorylation through the activation of Adenylate Cyclase
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Ion homeostasis
- Degradation of GLI1 by the proteasome
- Degradation of GLI2 by the proteasome
- GLI3 is processed to GLI3R by the proteasome
- Hedgehog 'off' state
- Anchoring of the basal body to the plasma membrane
- CD209 (DC-SIGN) signaling
- MAPK6/MAPK4 signaling
- RET signaling
- AURKA Activation by TPX2
- HDL assembly
- ROBO receptors bind AKAP5
- Loss of phosphorylation of MECP2 at T308
- Regulation of MECP2 expression and activity
- Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
- ADORA2B mediated anti-inflammatory cytokines production
- ADORA2B mediated anti-inflammatory cytokines production
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated IL10 synthesis
- Factors involved in megakaryocyte development and platelet production
|
- Pentanal
- Balanol Analog 2
- 3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate
- Phosphonothreonine
- Balanol Analog 1
- 3,5-Diiodotyrosine
- Balanol
- Dexfosfoserine
- S,S-(2-Hydroxyethyl)Thiocysteine
- Hydroxyfasudil
- (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
- (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine
- (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE
- (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
- (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
- N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE
- 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione
- (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE
- N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE
- (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
- (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- H-89
- 5-(2-methylpiperazine-1-sulfonyl)isoquinoline
- N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE
- 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
- 3-pyridin-4-yl-1H-indazole
- 5-benzyl-1,3-thiazol-2-amine
- 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium
- Fasudil
- Myristic acid
- A-674563
- 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE
- Y-27632
- Ellagic acid
- Fostamatinib
|
|
|
PRKAR1A |
protein kinase cAMP-dependent type I regulatory subunit alpha |
- PKA activation
- PKA activation in glucagon signalling
- DARPP-32 events
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Vasopressin regulates renal water homeostasis via Aquaporins
- CREB1 phosphorylation through the activation of Adenylate Cyclase
- Hedgehog 'off' state
- ADORA2B mediated anti-inflammatory cytokines production
- FCGR3A-mediated IL10 synthesis
- Factors involved in megakaryocyte development and platelet production
|
- (Rp)-cAMPS
- Cyclic GMP
- Cyclic adenosine monophosphate
- GEM-231
|
- Pigmented micronodular adrenocortical disease (PPNAD)
|